The Effect of Contrast Media on Treatment Planning and Dose Calculation in Radiation Therapy of Pelvis Cancers

Document Type : Original Article (s)

Authors

1 Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 MSc Student, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Medical Physics, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

4 Oncology-Radiation Therapist, Shafa Hospital, Kerman, Iran

Abstract

Background: Using contrast media is very important in diagnosis and identification of organ from the surrounding tissue. Contrast media can alter radiation absorption of studied organs following by enhanced image contrast. This study aimed to assess the influence of contrast media on treatment planning and dose calculation in radiation therapy of pelvic cancers.Methods: Six patients with pelvic area cancer with two sets of computed tomography (CT) images, one with contrast media and another without it, were studied and the effects of contrast media were studied.Findings: After using contrast media, an increase of 2.91% in monitor unit (MU) for right lateral (RL) field and decreases of 0.59%, 0.75%, and 1.47% in monitor unit anterior-posterior (AP), posterior-anterior (PA), and left lateral (LL) fields was obtained in rectum cancer, respectively. For bladder cancer, a decrease of 0.34% in monitor unit for AP filed and increases of 1.57%, 0.46%, and 0.39% in monitor unit for PA, RL and LL fields was calculated, respectively. For cervix cancer, a decrease of 1.1% for AP field and an increase of 0.68% for PA field were obtained.Conclusion: Regarding dose-volume histograms (DVHs) and calculated monitor units, the results showed that the dose differences between the plans for the CT images with and without contrast media were less than 1%. Of course to ensure the effect of contrast media on the amount of delivered dose to the target organ, study on more patients is recommended.

Keywords

References

  1. Shahbazi-Gahrouei D, Gookizadeh A, Abdollahi M. Comparison of conventional radiotherapy techniques with different energies in treating prostate cancer, employing a designed pelvis phantom. J Med Sci 2008; 8(4): 429-32.
  2. Shahbazi-Gahrouei D. Possible effect of background radiation on cancer incidence in Chaharmahal and Bakhtiari province. J Radiat Res 2003; 1(3): 171-4.
  3. Shahbazi-Gahrouei D, Abdolahi M. A novel method for quantitative analysis of anti-MUC1 expressing ovarian cancer cell surface based on magnetic cell separation. J Med Sci 2012; 12(8): 256-66.
  4. Shahbazi-Gahrouei D, Abdolahi M. Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection. J Med Phys 2013; 38(4): 198-204.
  5. Arab-Bafrani Z, Shahbazi-Gahrouei D, Abbasian M, Fesharaki M. Multiple MTS assay as the alternative method to determine survival fraction of the irradiated HT-29 colon cancer cells. J Med Signals Sens 2016; 6(2): 112-6.
  6. Rezaee V, Shahbazi-Gahrouei D, Monadi S, Saeb M. Evaluation of error doses of treatment planning software using solid anthropomorphic phantom. J Isfahan Med Sch 2016; 34(393): 908-13. [In Persian].
  7. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56(1): 83-8.
  8. Bohm I, Heverhagen JT, Klose KJ. Classification of acute and delayed contrast media-induced reactions: proposal of a three-step system. Contrast Media Mol Imaging 2012; 7(6): 537-41.
  9. Shahbazi-Gahrouei D. Novel MR imaging contrast agents for cancer detection. J Res Med Sci 2009; 14(3): 141-7.
  10. Shahbazi-Gahrouei D, Williams M, Allen BJ. Synthesis and application of new gadolinium-porphyrins as potential MR imaging contrast agents for cancer detection in nude mice. Iran Biomed J 2017; 5(2-3): 87-95.
  11. Akmali Z, Shahbazi-Gahrouei D, Mosleh-Shirazi MA, Baradaran-Ghahfarokhi M, Fallahian N, Sherkat S. Design and fabrication of a 4-dimentional of respiratory phantom for studying tumor movement in radiotherapy with magnetic resonance imaging. J Isfahan Med Sch 2015; 33(333): 631-42. [In Persian].
  12. Weber DC, Rouzaud M, Miralbell R. Bladder opacification does not significantly influence dose distribution in conformal radiotherapy of prostate cancer. Radiother Oncol 2001; 59(1): 95-7.
  13. Lees J, Holloway L, Fuller M, Forstner D. Effect of intravenous contrast on treatment planning system dose calculations in the lung. Australas Phys Eng Sci Med 2005; 28(3): 190-5.
  14. Letourneau D, Finlay M, O'Sullivan B, Waldron JN, Cummings BJ, Ringash J, et al. Lack of influence of intravenous contrast on head and neck IMRT dose distributions. Acta Oncol 2008; 47(1): 90-4.
  15. Shi W, Liu C, Lu B, Yeung A, Newlin HE, Amdur RJ, et al. The effect of intravenous contrast on photon radiation therapy dose calculations for lung cancer. Am J Clin Oncol 2010; 33(2): 153-6.
  16. Ramm U, Damrau M, Mose S, Manegold KH, Rahl CG, Bottcher HD. Influence of CT contrast agents on dose calculations in a 3D treatment planning system. Phys Med Biol 2001; 46(10): 2631-5.
  17. Yamada S, Ueguchi T, Ogata T, Mizuno H, Ogihara R, Koizumi M, et al. Radiotherapy treatment planning with contrast-enhanced computed tomography: feasibility of dual-energy virtual unenhanced imaging for improved dose calculations. Radiat Oncol 2014; 9: 168.
  18. Jabbari N, Molazadeh M, Esnaashari O, Seyed Siahi M, Zeinali A. Influence of the intravenous contrast media on treatment planning dose calculations of lower esophageal and rectal cancers. J Cancer Res Ther 2014; 10(1): 147-52.
  19. Shibamoto Y, Naruse A, Fukuma H, Ayakawa S, Sugie C, Tomita N. Influence of contrast materials on dose calculation in radiotherapy planning using computed tomography for tumors at various anatomical regions: a prospective study. Radiother Oncol 2007; 84(1): 52-5.
Journal of Isfahan Medical School
Volume 34, Issue 408 - Serial Number 408
September and October 2017
Pages 1389-1394

Files

History

  • Receive Date: 16 September 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics